A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine
Latest Information Update: 03 Jul 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Monoclonal antibodies (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms NorMig
Most Recent Events
- 03 Jul 2025 New trial record